Fewer adults and children with sickle cell disease (SCD) have sought medical care for disease-related events during the COVID-19…
Articles by Steve Bryson, PhD
Researchers at the University of York in the U.K. have been awarded a $3.1 million (£2.3 million) grant to accelerate…
Higher doses of FTX-6058, an investigational oral treatment for sickle cell disease (SCD), effectively raised hemoglobin messenger RNA…
IMR-687 (tovinontrine), an experimental oral therapy for sickle cell disease (SCD), reduced the rate of painful vaso-occlusive crisis (VOC),…
Enrollment is underway for a Phase 1/2 trial evaluating the safety and efficacy of EDIT-301, an experimental gene editing cell…
Oxbryta (voxelotor), Global Blood Therapeutics’ first-in-class oral therapy for sickle cell disease (SCD), has won the 2021 Prix…
The U.S. Food and Drug Administration (FDA) has agreed to consider Global Blood Therapeutics’ (GBT) request to expand the use…
A Promising Innovative Medicine (PIM) designation has been granted to Oxbryta (voxelotor), a treatment to reduce the destruction of…
Machine learning tools can identify sickle cell disease (SCD) patients at high risk of progressive kidney disease as early…
A non-viral, CRISPR-based gene-editing tool showed a potential to reverse mutations that cause…